Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | GRK2 | P25098 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17880525 | 0.94 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL17880547 | 0.89 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL17880544 | 0.88 | MAPT (0.50) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL17880554 | 0.87 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL17880532 | 0.86 | MEN1 (0.53) | NPC1RAB9AKCNQ3KCNQ2L3MBTL1 | |
| SCHEMBL17880500 | 0.84 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL17880533 | 0.84 | MEN1 (0.49) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL19380180 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL17880552 | 0.84 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL17880531 | 0.83 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | NOVIRA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9765050-B2 | Pyridyl reverse sulfonamides for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051000-A1 | Pyridyl Reverse Sulfonamides For HBV Treatment | HAVCR2, HCCS, NR1H4 | NPC1 798/4885RAB9A 2638/4885SMN1; SMN2 4649/4885 |
| US-20150166486-A1 | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS | SYK, ZAP70, TYRO3 | NPC1 4541/4885RAB9A 3346/4885SMN1; SMN2 4108/4885 |
| US-20160185748-A1 | PYRIDYL REVERSE SULFONAMIDES FOR HBV TREATMENT | HAVCR2, HCCS, NR1H4 | NPC1 798/4885RAB9A 2638/4885SMN1; SMN2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.